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Summary
Several transcriptional activators, called ‘‘classical’’ because
each bears a natural acidic activating region attached to a
DNA binding domain, are proteolytically unstable in yeast,
and it has been suggested that this instability is required
for transcriptional activation [1–3]. Here we test the gener-
ality of that proposal by examining a set of activators (called
‘‘nonclassical’’) that lack activating regions. These activators
(e.g., LexA-Gal11) comprise a LexA DNA binding domain
fused to a component of the Mediator and are believed to
insert the latter into the Mediator and recruit it (and, indi-
rectly, other components required for transcription) to a
gene bearing LexA sites [4–8]. We find that three, and only
three, Mediator subunits, all from its tail domain, work as
activators when fused to LexA. All three are unstable, and
for the case analyzed in detail, stabilization decreases
activity. Thus, to the extent tested, both classical and
nonclassical activators work most efficiently when proteolyt-
ically unstable.
Results and Discussion
We constructed genes encoding fusion proteins of the form
Med-LexA by integrating LexA DNA at the ends of genes
encoding 17 of 25 known Mediator subunits. Each hybrid
gene was expressed from its native promoter at its ordinary
chromosomal location. Table 1 shows the transcriptional
activating function of each fusion measured by b-galactosi-
dase levels expressed from an integrated GAL1-LacZ reporter
bearing LexA sites. Only three fusions elicited significant levels
of b-galactosidase: those bearing, in addition to LexA, the
Mediator subunits Gal11, Med2, and Pgd1. All three of these
subunits are found in the tail domain of the Mediator.
Figure 1A shows that all three of the fusions that activate
transcription—Gall1-LexA, Med2-LexA, and Pgd1-LexA—are
unstable as visualized by their degradation following addition
of cycloheximide. The figure also shows that, in contrast,
fusions bearing either a subunit from the head domain (Srb2)
or middle domain (Med1), which do not activate, are not
unstable. We did not test the stabilities of other Med-LexA
fusions. Figure 1B shows that, whereas the native Gal11
protein is unstable, the native forms of Med2, Pgd1, and
LexA are not. We chose Med2-LexA for further study.*Correspondence: m-ptashne@mskcc.orgAs noted in the Summary, Mediator proteins fused to a DNA
binding domain (DBD) activate transcription by integrating
into the Mediator and recruiting the complex to the promoter
by virtue of the attached DBD. This model was supported by
the finding that LexA-Gal11 complemented the defect caused
by deletion of wild-type (WT) GAL11 [4]. The experiment
depicted in Figure S1, available online, extends this observa-
tion to the case of Med2-LexA. Thus, as shown in the figure,
Med2-LexA corrects the growth defect caused by deletion of
MED2 itself.
We considered the possibility that proteolysis of Med2-LexA
occurred only as it activated transcription. One of the experi-
ments depicted in Figure 2 shows that this cannot be so.
Thus, although the transcriptional activating activity of
Med2-LexA was inhibited (squelched) by overexpression of
LexA (Figure 2A), the fusion protein, expressed at normal
levels, remained unstable (Figure 2B). Thus, even under
conditions in which the fusion protein does not activate
transcription, it remains unstable. In contrast to the effect of
overexpressing LexA, overexpression of Med2 caused not
only an apparent inhibition of the activity of the fusion protein
(Figure 2A) but also a significant decrease in its levels (Fig-
ure 2C). At these lower levels, the fusion protein remains
unstable (Figure 2C). The result suggests that a negative autor-
egulatory effect maintains the concentration of Med2 below
some specified level (i.e., at high concentrations, Med2,
directly or indirectly, turns off expression of its own gene).
Another possibility is that high concentrations of Med2 dis-
place Med2-LexA from the Mediator and thereby, for some
reason, render it more sensitive to proteolysis.
Figure 3A shows the effect of damaging the 20S proteasome
on stability of Med2-LexA. The cells bore the mutations pre1-1
and pre4-1, which render the proteasome heat sensitive, and
the cells were grown at a nonpermissive temperature. As
shown in the figure, the activator was stabilized under these
conditions [9]. Figure 3B shows that the fusion was also stabi-
lized by growth at the nonpermissive temperature of a mutant
strain bearing the cdc53-1 temperature-sensitive (ts) mutation
[10]. This mutation inactivates, at the high temperature, the
scaffold subunit cullin found in the Skp1-Cullin-F-box (SCF)
family of E3 ligases.
We introduced Med2-LexA, on a plasmid, into 20 strains,
each of which is deleted for or carries a temperature-sensitive
mutation in one or another of 20 different F-box proteins.
These F-box proteins are known or predicted to be the speci-
ficity determinants of the SCF-type E3 ligases [2, 11]. In only
one such strain, that bearing deletion of DIA2, was Med2-
LexA found to be stable (data not shown). When expressed
from its native MED2 promoter, Med2-LexA was also stable
in the dia2D strain (Figure 3C). Dia2 has not been found to
be involved in degradation of any classical transcriptional
activator. In this strain, Med2-LexA stimulated production of
b-galactosidase from the reporter at least 5-fold less efficiently
than it did in a WT strain. The level of LacZ mRNA was also
decreased by the dia2 deletion, but the effect was less
dramatic than the effect on the protein level (Figure 3D). In a
control experiment, induction of GAL1 mRNA by Gal4 was
identical in WT and dia2-deleted strains (data not shown).
Table 1. Activities of Nonclassical Activators
Mediator Domains Med-LexA Fusions Activities
Tail Gal11 52
Med2 758
Pgd1 638
Sin4 0
Rgr1 3
Middle Nut1 1
Med1 1
Med9 2
Med4 1
Med10 1
Med7 4
Head Srb5 1
Srb2 0
Srb4 0
Rox3 1
Kinase Srb9 0
Srb10 1
Genes encoding each of the indicated Mediator subunits were fused, at their
30 ends, to the LexA gene. Each fusion protein was expressed in a strain
bearing an integrated reporter comprising two LexA sites upstream
of GAL1-LacZ gene. Cells were grown overnight and were assayed for
b-galactosidase activity. The expression levels and stabilities of five fusions
were tested and are shown in Figure 1.
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Figure 1. Protein Stabilities
(A) Gal11-LexA, Med2-LexA, Pgd1-LexA, Med1-LexA, and Srb2-LexA fusion
proteins. Cycloheximide (CHX) was added to growing cells expressing each
of the indicated fusion proteins. Protein levels were measured at various
times thereafter by western blotting with anti-LexA antibody. Carboxypep-
tidase Y (CPY) was used as a loading control (not shown).
(B) The native forms of Med2, Pgd1, Gal11, and LexA. Cycloheximide chase
experiments were performed as described in (A). Antibodies used were
anti-Myc, anti-Med2, anti-LexA, anti-Gal11, and anti-CPY.
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protein quality control pathway in the nucleus [12], had no
effect on the stability of Med2-LexA or Pgd1-LexA, the two
fusion proteins tested.
We undertook these experiments to challenge the notion
that transcriptional activators must be proteolytically unstable
to work with full efficiency. We reasoned that, were the insta-
bility of classical activators such as Gal4 and Gcn4 some
accidental attribute of their activating regions, then an entirely
separate class of activators that work in a different way would,
in some cases at least, work with full efficiency as stable
proteins. But this expectation has been confounded. Of the
three Mediator components that work as activators when
attached to a DNA binding domain, one (Gal11) is inherently
unstable and the other two (Med2 and Pdg1) become unstable
when attached to LexA. We do not know why these latter two
fusions are unstable—it is possible that instability is some
accidental effect of fusing these otherwise stable subunits to
LexA. Nevertheless, the instability is required for full activity:
where we eliminated a relevant F-box protein (Dia2) and
rendered a fusion protein (Med2-LexA) stable, its activating
activity was reduced. Thus, our results are consistent with
the idea that instability of transcriptional activators contributes
to the efficiencies with which they work. Perhaps transcrip-
tional complexes must continually turn over to sequentially
bring to the promoter components required for steps leading
and subsequent to initiation, and activator instability can
help facilitate this turnover. A hint that this idea might be
correct was the finding of Muratani et al. [2] that stabilization
of Gal4 (caused by deleting DSG1) has a much greater effect
on translation of the mRNA read from the promoter than it
does on mRNA production itself. They further showed that
the Pol II recruited by Gal4 working in the dsg1 mutant was
deficient in Ser5 phosphorylation of its carboxy-terminal
domain and in recruitment of the mRNA capping complex.
We find here (see Figure 3D) that increasing the stability of
Med2-LexA (by deleting DIA2) preferentially decreased the
amount of translated protein compared to that of the mRNA
elicited by the fusion activator.An additional finding reported here is that, among a wide
array of Med-LexA fusion proteins tested, only those bearing
one of three subunits from the Mediator tail domain work
efficiently as activators. An array of previous reports has
suggested that components of the tail domain (and in partic-
ular Gal11) are targets of transcriptional activating regions
[4–8, 13–15]. The results, taken with those presented here,
might reflect some stereospecific restrictions on how recruit-
ment can be successfully effected, either by a classical or a
nonclassical activator, to build a transcriptional complex.
Experimental Procedures
Yeast Strains and Plasmids
The parental Saccharomyces cerevisiae strain used in most of this study is
JPY5 (MATa, ura3-52 his3D200 leu2D1 trp1D63 lys2D385), which was
derived from the S288C background [4]. The cdc53-1 strain and its corre-
sponding wild-type strain were derived from the W303 background [16].
The pre1-1 pre4-1 strain and its corresponding wild-type strain were
obtained from Pengbo Zhou [17]. Strains bearing Myc-tagged MED2 or
PGD1 were constructed via a standard method [18], and a modified version
of this method, which involves replacing Myc with LexA, was used to
construct strains expressing the Med-LexA fusion proteins. The med2D
and dia2D strains were constructed by deleting their corresponding open
reading frames via a one-step replacement method [18].
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Figure 3. The Activity of a Stabilized Med2-LexA
(A) Inactivation of the 20S protease complex of the proteasome. Wild-type
(WT) and pre1-1 pre4-1 cells (which bear double mutations of the 20S
proteasome subunits), both bearing the MED2-LexA fusion gene, were
grown overnight to mid-log phase at 30C and then shifted to 37C for
1 hr. A cycloheximide chase experiment was performed.
(B) Inactivation of an SCF-type E3 ligase. WT and cdc53-1 (which bears
a mutation in the cullin subunit of SCF-type E3 ligases) cells, both bearing
the MED2-LexA fusion gene, were grown overnight to mid-log phase at
30C and then shifted to 37C for 1 hr. A cycloheximide chase experiment
was performed.
(C) Stability of Med2-LexA in a strain deleted for the specific E3 F-box
protein Dia2. Cells deleted or wild-type for DIA2 (which encodes an F-box
protein), and also bearing the MED2-LexA fusion gene, were exposed to
cycloheximide as assayed in the experiments depicted in Figure 1.
(D) Activity of Med2-LexA in a strain deleted for DIA2. WT and dia2D cells,
both bearing MED2-LexA fusion gene, were assayed for both b-galactosi-
dase activities and LacZ mRNA levels. b-galactosidase activity and LacZ
mRNA level in WT cells were set to 1. Error bars denote standard deviation.
0       15 45 90CHX 0 15 45 90 min
+_
Med2-LexA
CPY
LexA
overexpression
C
B
0
0.2
0.4
0.6
0.8
1
1.2
Vector LexA Med2
R
el
at
iv
e
-
ga
l a
ct
iv
iti
es
A
0 15 45 90CHX 0 15 45 90 min
Med2-LexA
CPY
Med2
overexpression +
_
Figure 2. Effects of Overexpression of LexA and Med2
(A–C) Cells bearing MED2-LexA and an integrated 2LexA-GAL1-LacZ
reporter were transformed with plasmids overexpressing either LexA or
Med2 from the ACT1 promoter, or with the vector alone. Cells were grown
overnight and were assayed for b-galactosidase activity (A). Error bars
denote standard deviation. Cycloheximide chase experiments were per-
formed on cells overexpressing LexA alone (B) or Med2 alone (C).
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870The reporter plasmid for integration carrying two LexA sites upstream of
GAL1-LacZ was described previously [4]. A plasmid overexpressing Med2-
LexA from the ACT1 promoter was constructed by inserting the MED2 gene
into a plasmid bearing the LexA gene attached to the ACT1 promoter [4].
Cell Growth Assays
Cells were grown overnight to mid-log phase in YPD media and were
washed and diluted with water to 0.1 at OD600. Then a series of 103 dilu-
tions were made, and 5 ml of each dilution was spotted on YPD (Glucose)
and YPGal (Galactose) plates. Pictures were taken after cells were grown
at 30C for 3 days.
b-Galactosidase Assays
b-galactosidase activity was measured as described previously [19]. Each
assay was performed at least in duplicate, and the standard error was
less than 20%. Relative activities are reported with average WT activity
set to 1.
Cycloheximide Chase Assays
Protein degradation was assessed by cycloheximide chase assays as
described in Muratani et al. [2]. Cells were grown in appropriate synthetic
complete media containing 2% glucose overnight to mid-log phase. Then
cycloheximide was added to the culture (50 mg/ml final concentration),
samples were taken at the indicated time points, and steady state levels
of protein of interest were visualized by western blotting with appropriate
antibodies. The antibodies used were anti-LexA (ab14553 from Abcam),
anti-Carboxypeptidase Y (CPY, A6428 from Molecular Probes), anti-Med2
(sc-28058 from Santa Cruz Biotechnology), anti-Myc (sc-40 from Santa
Cruz Biotechnology), and anti-Gal11 (generated in our laboratory). In cases
in which temperature-sensitive mutants were involved, WT and ts cells were
grown at the permissive temperature (25C) overnight to mid-log phase and
then shifted to the restrictive temperature (37C) for 1 hr before cyclohexi-
mide was added.Reverse Transcriptase-Polymerase Chain Reaction Analysis
RNA was extracted, reverse transcribed, and quantified by reverse
transcriptase-polymerase chain reaction, as described previously [20]. For
cDNA measurement, primers used are 50-GCCGCTACAGTCAACAGCAA-30
and 50-ATATTCAGCCATGTGCCTTCTTC-30 for LacZ cDNA and 50-CGT
TCCAATTTACGCTGGTT-30 and 50-GGCCAAATCGATTCTCAAAA-30 for
ACT1 cDNA. LacZ mRNA levels were normalized to those of ACT1. Relative
LacZ mRNA was reported with average WT mRNA level set to 1.Supplemental Information
Supplemental Information includes one figure and can be found with this
article online at doi:10.1016/j.cub.2010.03.029.
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